Canadian Medical Assocation

CMA activity and submissions

2018

August 30, 2018

Open letter to Premier Doug Ford and Health Minister Christine Elliott

CMA signs an open letter reinforcing the need to provide greater and more equitable access to supervised consumption sites in Ontario

August 14, 2018

CMA response: Consultation on Regulatory Amendments regarding Tramadol

To protect Canadians’ health and safety, the CMA advises tramadol be placed on Schedule 1 of the Controlled Drugs and Substances Act

July 18, 2018

CMA response: Consultation on Restriction of Marketing and Advertising of Opioids

The CMA supports Health Canada’s efforts to restrict the ability of drug manufacturers to advertise opioids to health care practitioners
2017

November 7, 2017

CMA submission on Non-Prescription Availability of Low-Dose Codeine Products

In the interest of promoting public health and patient safety, the CMA endorses the requirement that all products containing low-dose codeine be sold by prescription only

August 22, 2017

Opioids Session on Periscope

At CMA’s 150th General Council in Quebec City, experts discuss the opioid crisis in Canada as part of a Facing Canada’s Opioids Crisis session

April 6, 2017

CMA submission on the study of Bill C-37: An Act to amend the Controlled Drugs and Substances Act

The CMA makes recommendations to the Senate Committee on Legal and Constitutional Affairs about Bill C-37, An Act to amend the Controlled Drugs and Substances Act and to make related amendments to other Acts
2016

October 18, 2016

CMA statement to the House of Commons Standing Committee on Health

Dr. Jeff Blackmer, CMA Vice-president of Medical Professionalism, speaks before the House of Commons Standing Committee on Health about Canada’s escalating public health crisis related to problematic opioid and fentanyl use

March 19, 2016

CMA response: Consultation on the Prescription Drug List: Naloxone

In response to Health Canada’s consultation on the prescription drug list, the CMA advocates for increased access to naloxone for emergency treatment of opioid overdose outside hospitals
2015

May 30, 2015

Harms Associated with Opioids and other Psychoactive Prescription Drugs

A CMA policy offers background on the harms associated with opioids and other psychoactive prescription drugs subject and outlines the elements of a comprehensive national strategy to address them

May 14, 2015

CMA submission to the Senate Standing Committee on Legal and Constitutional Affairs on Bill C-2: An Act to Amend the Controlled Drugs and Substances Act

The CMA presents its concerns with Bill C-2 before the Senate Standing Committee on Legal and Constitutional Affairs, including that the new legislation could make it harder to create new supervised consumption sites
2014

October 28, 2014

CMA submission to the House of Commons Standing Committee on Public Safety and National Security on Bill C-2: An Act to Amend the Controlled Drugs and Substances Act

Concerns about the potential of Bill C-2 impede the creation of new supervised consumption sites feature in the CMA’s submission to the House of Commons Standing Committee on Public Safety and National Security

August 26, 2014

CMA response on Tamper Resistance under the Controlled Drugs and Substances Act

The CMA advocates for regulations requiring products containing certain controlled substances to be tamper-resistant as a condition for sale in Canada

March 26, 2014

CMA submission on the Senate study on prescription pharmaceuticals

In support of the Senate Committee on Social Affairs, Science and Technology study on prescription pharmaceuticals in Canada, the CMA recommends ways for the federal government to address the unintended consequences of prescription pharmaceuticals and support public health, quality care and patient safety

March 17, 2014

CMA submission on the Review of Controlled Drugs and Substances Act

The CMA’s response to Health Canada’s consultation on the Controlled Drugs and Substances Act and its regulations recommends new measures and mechanisms for improving public health and safety, including enhancements to controlled substance approval, labelling and safety monitoring
2013

November 27, 2013

The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada

The CMA supports the House of Commons Standing Committee on Health study on the government’s role in addressing prescription drug abuse in Canada with background on the issue and recommendations for tackling the issue, including national strategies for reducing misuse and promoting optimal prescribing

Tools & Resources


Tool

Guideline for management of opioid use disorder

The opioid use disorder management guidelines developed by the Canadian Research Initiative in Substance Misuse details optimal strategies for treating opioid addiction, and recommends opioid agonist treatment.

Resource

Addressing stigma

The stigma surrounding mental illness (including opioid use disorder) remains pervasive. This Centre for Addiction and Mental Health webpage lists seven things you can do to help reduce this stigma, provides an online tutorial with facts about mental illness and practical strategies for combating stigma, and more.

Tool

Opioid tapering template

Based on the best available evidence, the Centre for Effective Practice’s Opioid Tampering Template can help you evaluate opioid therapies and reduce patients’ dosages safely and effectively.

Tool

Opioid prescription manager

The Opioid Manager is a clinical tool that can help you manage opioid prescriptions for patients experiencing chronic, non-cancer pain. It includes a checklist of important points to discuss, document and include in the record of any patient starting or continuing an opioid trial.

Get Involved

Join the conversation

The CMA provides grants and supports communities of interest to help physicians tackle issues that matter to the medical professions and health care in Canada.

 

Have your say

Weigh in on a variety of health policy and professional issues by joining our CMA Member Voice e-Panel. Your feedback helps shape the direction of the policy and advocacy work we do on behalf of the profession. In 2014, we surveyed members to learn more about their experience with prescribing opioids.

Related Resources


Opioid-related harms

The harms associated with opioids and other psychoactive prescription drugs are a significant public health and patient safety issue. This CMA policy provides key background and the key components of an effective national strategy to address opioid-related harms.

Opioid Wisely recommendations

As part of its Opioid Wisely campaign, Choosing Wisely Canada introduced 15 speciality-specific recommendations to help physicians determine when opioids are not appropriate as a first-line therapy. The campaign is supported by more than 30 organizations representing doctors, pharmacists, nurse practitioners and other health professionals as well as patients and their families.

Federal action plan and response to Canada’s opioid crisis

Canada’s national opioid crisis is a complex health and social issue demanding a thorough, evidence-based response. This Government of Canada webpage includes essential information about the federal government’s response, the importance of supervised consumption sites and more.